We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-2.94%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.56B
AUM Growth
-$105M
Cap. Flow
+$128M
Cap. Flow %
4.99%
Top 10 Hldgs %
48.1%
Holding
79
New
9
Increased
20
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$66.5M
2
AMRN
Amarin Corp
AMRN
+$47.6M
3
WHWK
Whitehawk Therapeutics
WHWK
+$35M
4
TYRA icon
Tyra Biosciences
TYRA
+$32.4M
5
KYMR icon
Kymera Therapeutics
KYMR
+$31.9M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$156M
2
ARGX icon
argenx
ARGX
+$90.3M
3
RLAY icon
Relay Therapeutics
RLAY
+$29.9M
4
FBRX icon
Forte Biosciences
FBRX
+$19.9M
5
IMVT icon
Immunovant
IMVT
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.03%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
51
DELISTED
Elevation Oncology
ELEV
$12.4M 0.48%
1,590,298
+7
+0% +$76
CDTX
52
DELISTED
Cidara Therapeutics
CDTX
$10.7M 0.42%
238,845
+21,500
+10% +$817K
ELTX icon
53
Elicio Therapeutics
ELTX
$74.1M
$10.5M 0.41%
107,130
+3,480
+3% +$376K
NUVL
54
DELISTED
Nuvalent
NUVL
$10.1M 0.39%
+448,512
New +$13M
LITS
55
Lite Strategy Inc
LITS
$32.8M
$9.75M 0.38%
176,603
– –
ANAB icon
56
AnaptysBio
ANAB
$1.56B
$9.07M 0.35%
334,398
-474,312
-59% -$12M
MIRM icon
57
Mirum Pharmaceuticals
MIRM
$6.58B
$8.68M 0.34%
+435,936
New +$7.09M
ELDN icon
58
Eledon Pharmaceuticals
ELDN
$259M
$8.43M 0.33%
1,363,435
+250,000
+22% +$1.75M
MOLN
59
Molecular Partners
MOLN
$8.27M 0.32%
+419,008
New +$8.24M
IVA
60
Inventiva
IVA
$1.04B
$7.71M 0.3%
544,500
+437,500
+409% +$5.77M
GNCA
61
DELISTED
Genocea Biosciences, Inc.
GNCA
$7.7M 0.3%
4,012,404
– –
PHXM
62
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$7.59M 0.3%
131,466
– –
CRVS icon
63
Corvus Pharmaceuticals
CRVS
$1.1B
$6.63M 0.26%
1,370,947
-2,307,679
-63% -$6.83M
RNTX
64
Rein Therapeutics
RNTX
$63.3M
$5.37M 0.21%
263,278
– –
GLMD icon
65
Galmed Pharmaceuticals
GLMD
$4.96M
$5.02M 0.2%
9,998
– –
EUCRU
66
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$4.96M 0.19%
500,000
– –
FLACU
67
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$4.93M 0.19%
500,000
– –
FVAM
68
DELISTED
5:01 Acquisition Corp
FVAM
$4.9M 0.19%
500,000
– –
RACB
69
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.83M 0.19%
500,000
– –
XFOR icon
70
X4 Pharmaceuticals
XFOR
$372M
$4.49M 0.18%
28,263
– –
ABOS icon
71
Acumen Pharmaceuticals
ABOS
$155M
$4.3M 0.17%
+289,663
New +$4.82M
FWP
72
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.99M 0.12%
432,892
-95,622
-18% -$840K
JYAC
73
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.93M 0.11%
300,000
– –
RZLT icon
74
Rezolute
RZLT
$449M
$1.42M 0.06%
190,815
– –
RNAC icon
75
Cartesian Therapeutics
RNAC
$221M
$1.33M 0.05%
10,656
-45,793
-81% -$5.53M
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2021 Portfolio in Review

As of Q3 2021, BVF Inc held 79 positions worth $2.56B, down 3.9% from $2.67B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $128M of net new capital in Q3 2021, opening 9 new positions and adding to 20 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 1,119,733 shares worth $58.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $90.3M trimmed.

  • BVF Inc's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 1,119,733 shares worth $58.9M.
  • BVF Inc added most to Amarin Corp in Q3 2021, an estimated $47.6M increase.
  • BVF Inc's biggest Q3 2021 reduction was argenx, cutting an estimated $90.3M.
  • BVF Inc fully exited Merus in Q3 2021, selling an estimated $156M.
  • BVF Inc's ten largest holdings make up 48% of its $2.56B portfolio in Q3 2021.
  • BVF Inc opened 9 new positions and closed 4 in Q3 2021.
  • BVF Inc's portfolio value fell 3.9% quarter-over-quarter to $2.56B.

Based on BVF Inc's 13F filing for Q3 2021, filed 15 Nov 2021.